These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35608016)

  • 1. High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence.
    Anderson K; Pietersen E; Shepherd BE; Bian A; Dheda K; Warren R; Sterling TR; van der Heijden YF
    HIV Med; 2022 Nov; 23(10):1085-1097. PubMed ID: 35608016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.
    Daniels JF; Khogali M; Mohr E; Cox V; Moyo S; Edginton M; Hinderaker SG; Meintjes G; Hughes J; De Azevedo V; van Cutsem G; Cox HS
    PLoS One; 2015; 10(11):e0142873. PubMed ID: 26555134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India.
    Isaakidis P; Das M; Kumar AM; Peskett C; Khetarpal M; Bamne A; Adsul B; Manglani M; Sachdeva KS; Parmar M; Kanchar A; Rewari BB; Deshpande A; Rodrigues C; Shetty A; Rebello L; Saranchuk P
    PLoS One; 2014; 9(10):e110461. PubMed ID: 25333696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mycobacterial drug resistance patterns on patients' survival: a cohort study in Thailand.
    Anuwatnonthakate A; Whitehead SJ; Varma JK; Silachamroon U; Kasetjaroen Y; Moolphate S; Limsomboon P; Inyaphong J; Suriyon N; Kavinum S; Chiengson N; Tunteerapat P; Kaewkungwal J
    Glob J Health Sci; 2013 Aug; 5(6):60-72. PubMed ID: 24171875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy.
    Sungkanuparph S; Eampokalap B; Chottanapund S; Bed ST; Manosuthi W
    J Med Assoc Thai; 2007 May; 90(5):884-8. PubMed ID: 17596041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa.
    Hom JK; Wang B; Chetty S; Giddy J; Mazibuko M; Allen J; Walensky RP; Losina E; Freedberg KA; Bassett IV
    PLoS One; 2012; 7(8):e43281. PubMed ID: 22912845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.
    Lee EG; Min J; Kang JY; Kim SK; Kim JW; Kim YH; Yoon HK; Lee SH; Kim HW; Kim JS
    BMC Infect Dis; 2020 Jun; 20(1):446. PubMed ID: 32576154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences among patients with drug resistant tuberculosis and HIV co-infection in Uganda: a countrywide retrospective cohort study.
    Baluku JB; Mukasa D; Bongomin F; Stadelmann A; Nuwagira E; Haller S; Ntabadde K; Turyahabwe S
    BMC Infect Dis; 2021 Oct; 21(1):1093. PubMed ID: 34689736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993.
    Chum HJ; O'Brien RJ; Chonde TM; Graf P; Rieder HL
    AIDS; 1996 Mar; 10(3):299-309. PubMed ID: 8882670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
    Podlekareva DN; Efsen AM; Schultze A; Post FA; Skrahina AM; Panteleev A; Furrer H; Miller RF; Losso MH; Toibaro J; Miro JM; Vassilenko A; Girardi E; Bruyand M; Obel N; Lundgren JD; Mocroft A; Kirk O;
    Lancet HIV; 2016 Mar; 3(3):e120-31. PubMed ID: 26939735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.
    Schnippel K; Shearer K; Evans D; Berhanu R; Dlamini S; Ndjeka N
    Int J Infect Dis; 2015 Oct; 39():89-94. PubMed ID: 26358856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America.
    TB:HIV Study writing Group
    AIDS; 2017 Jan; 31(3):375-384. PubMed ID: 28081036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistant TB prevalence study in 5 health institutions in Haiti.
    Hoffmann J; Chedid C; Ocheretina O; Masetti C; Joseph P; Mabou MM; Mathon JE; Francois EM; Gebelin J; Babin FX; Raskine L; Pape JW
    PLoS One; 2021; 16(3):e0248707. PubMed ID: 33735224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study.
    Bastard M; Sanchez-Padilla E; du Cros P; Khamraev AK; Parpieva N; Tillyashaykov M; Hayrapetyan A; Kimenye K; Khurkhumal S; Dlamini T; Perez SF; Telnov A; Hewison C; Varaine F; Bonnet M
    PLoS One; 2018; 13(3):e0193491. PubMed ID: 29518098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.
    Abebe G; Abdissa K; Abdissa A; Apers L; Agonafir M; de-Jong BC; Colebunders R
    BMC Res Notes; 2012 May; 5():225. PubMed ID: 22574696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.